60
Shanghai Pharma
601607.SS·SSEShanghai CNFounded 199455,000 employees
Large CappharmaPublicOncologyCardiology
Platform: Integrated
Market Cap
$10B
All Drugs
5
Clinical Trials
11
Failed / Terminated
2
FDA Approved
1
Stock Price & Catalysts (601607.SS)
Loading 601607.SS stock data...
Drug Pipeline (5 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pemitinib | 601-4633 | Preclinical | 2 | JAK1 | DLBCL | ||
| 601-626 | 601-626 | Approved | 4 | GIP-R | Gastric CaWM | ||
| Capitinib | 601-6046 | Phase 1 | 2 | C5 | AsthmaCeliac | ||
| 601-209 | 601-209 | Phase 2/3 | 1 | TYK2 | ALSEwing Sarcoma | ||
| 601-7487 | 601-7487 | Phase 2 | 2 | Menin | LGSAS |
SEC Filings & Financial Documents
SEC filings are not available for SSE-listed companies.
Shanghai Pharma trades on SSE (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (7)